Amalgamated Bank grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,685 shares of the biotechnology company’s stock after buying an additional 489 shares during the quarter. Amalgamated Bank’s holdings in United Therapeutics were worth $1,285,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also recently modified their holdings of UTHR. Quantbot Technologies LP grew its stake in shares of United Therapeutics by 537.3% during the third quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 822 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of United Therapeutics during the third quarter valued at approximately $156,000. SeaCrest Wealth Management LLC bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $178,000. HL Financial Services LLC bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $217,000. Finally, CIBC Asset Management Inc bought a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $220,000.
Several analysts have recently commented on UTHR shares. TheStreet raised shares of United Therapeutics from a “c+” rating to a “b” rating in a research note on Friday, December 15th. ValuEngine cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 2nd. Zacks Investment Research raised shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $160.00 price target on the stock in a research note on Monday, January 15th. BidaskClub raised shares of United Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, December 6th. Finally, Oppenheimer increased their price target on shares of United Therapeutics to $180.00 and gave the company an “outperform” rating in a research note on Friday, January 5th. Five analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $135.20.
United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $3.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.59 by $0.30. United Therapeutics had a net margin of 24.22% and a return on equity of 24.41%. The firm had revenue of $464.70 million for the quarter, compared to analysts’ expectations of $420.55 million. During the same period last year, the firm earned $4.12 earnings per share. The business’s revenue for the quarter was up 13.6% on a year-over-year basis. equities research analysts predict that United Therapeutics Co. will post 12.46 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “United Therapeutics Co. (UTHR) Shares Bought by Amalgamated Bank” was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/03/13/united-therapeutics-co-uthr-shares-bought-by-amalgamated-bank.html.
United Therapeutics Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.